SRR8518274
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- SPERMATOGENESIS+0.270
- PANCREAS_BETA_CELLS+0.160
- ANGIOGENESIS+0.140
- PROTEIN_SECRETION+0.120
- CHOLESTEROL_HOMEOSTASIS+0.100
- E2F_TARGETS+0.100
- ESTROGEN_RESPONSE_LATE+0.100
- OXIDATIVE_PHOSPHORYLATION+0.100
- UV_RESPONSE_UP+0.100
- KRAS_SIGNALING_DN+0.080
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.580
- INTERFERON_GAMMA_RESPONSE-0.530
- ALLOGRAFT_REJECTION-0.480
- IL6_JAK_STAT3_SIGNALING-0.380
- INFLAMMATORY_RESPONSE-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- COMPLEMENT-0.350
- IL2_STAT5_SIGNALING-0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | aMVAC.P_016_TURBT_S236 | — | — | 0.828 |
| 2 | SRR23303758 | — | — | 0.814 |
| 3 | 3bc40056-88b6-483c-8701-747eb6e851c4 | — | — | 0.804 |
| 4 | SRR13780262 | — | cohortSC | 0.804 |
| 5 | SRR8613793 | — | B | 0.794 |
| 6 | SRR25617889 | — | B | 0.784 |
| 7 | SRR8518380 | — | C | 0.782 |
| 8 | TCGA-05-4420-01A-01R-1206-07 | — | cohortA3 | 0.779 |
| 9 | TCGA-D8-A1XV-01A-11R-A14M-07 | — | B | 0.779 |
| 10 | TCGA-E9-A54X-01A-11R-A266-07 | — | B | 0.776 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.070 | Idelalisib | — uncovered |
| MYOGENESIS | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |